Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Plos One|April 18, 2020
Toward precision prescribing for methadone: Determinants of methadone depositionAndrew H Talal, Yuxin Ding, Charles S Venuto, et al.
British Journal of Clinical Pharmacology|October 28, 2019
Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334sCharles S Venuto, Yoninah S Cramer, Susan L Rosenkranz, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2017
Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling TechniquesCharles S Venuto, Marianthi Markatou, Yvonne Woolwine-Cunningham, et al.
Current Vascular Pharmacology|January 7, 2016
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related DisordersCindy Bednasz, Amneris E Luque, Barry S Zingman, et al.
Pharmacogenomics|February 28, 2007
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIVQing Ma, Daniel Brazeau, Barry S Zingman, et al.
Future Virology|February 16, 2016
Recent advances in management of the HIV/HCV coinfected patientCindy J Bednasz, Joshua R Sawyer, Anthony Martinez, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
The Lancet. Neurology|September 30, 2017
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validationJeanne C Latourelle, Michael T Beste, Tiffany C Hadzi, et al.
Therapeutic Drug Monitoring|November 15, 2017
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive ParticipantsCindy J Bednasz, Charles S Venuto, Qing Ma, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2019
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202Cindy J Bednasz, Charles S Venuto, Qing Ma, et al.
Pageof 4